A high-throughput cell-and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma

C Fenwick, P Turelli, C Pellaton, A Farina… - Science Translational …, 2021 - science.org
The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific
antibodies in the serum of an individual indicates previous infection or vaccination …

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

CW Tan, WN Chia, X Qin, P Liu, MIC Chen, C Tiu… - Nature …, 2020 - nature.com
A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed
to determine not only the infection rate, herd immunity and predicted humoral protection, but …

Crucial mutations of spike protein on SARS-CoV-2 evolved to variant strains escaping neutralization of convalescent plasmas and RBD-specific monoclonal …

C Ding, J He, X Zhang, C Jiang, Y Sun… - Frontiers in …, 2021 - frontiersin.org
Small number of SARS-CoV-2 epidemic lineages did not efficiently exhibit a neutralization
profile, while single amino acid mutation in the spike protein has not been confirmed in …

[HTML][HTML] A simple protein-based surrogate neutralization assay for SARS-CoV-2

KT Abe, Z Li, R Samson, P Samavarchi-Tehrani… - JCI insight, 2020 - ncbi.nlm.nih.gov
Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) mount a humoral immune response to the virus within a few weeks of infection, but …

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera

S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - MedRxiv, 2021 - medrxiv.org
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19

Y Kaku, T Kuwata, HM Zahid, T Hashiguchi, T Noda… - Cell reports, 2021 - cell.com
Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a
potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute …

[HTML][HTML] Infection-and vaccine-induced antibody binding and neutralization of the B. 1.351 SARS-CoV-2 variant

VV Edara, C Norwood, K Floyd, L Lai… - Cell host & …, 2021 - cell.com
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …

Function is more reliable than quantity to follow up the humoral response to the receptor-binding domain of SARS-CoV-2-spike protein after natural infection or COVID …

CA Sariol, P Pantoja, C Serrano-Collazo… - Viruses, 2021 - mdpi.com
Both the SARS-CoV-2 pandemic and emergence of variants of concern have highlighted the
need for functional antibody assays to monitor the humoral response over time. Antibodies …

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

B Bošnjak, SC Stein, S Willenzon, AK Cordes… - Cellular & molecular …, 2021 - nature.com
Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2
spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into …

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

J Hu, P Peng, K Wang, L Fang, F Luo, A Jin… - Cellular & molecular …, 2021 - nature.com
Coronaviruses are enveloped, positive-stranded RNA viruses that contain the largest known
RNA genomes to date. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …